Clinical role of serum tumor markers SCC, NSE, CA 125, CA 19-9, and CYFRA 21-1 in patients with lung cancer.

Laboratory medicine Pub Date : 2023-11-02 DOI:10.1093/labmed/lmad020

Aiwen Sun

{"title":"Clinical role of serum tumor markers SCC, NSE, CA 125, CA 19-9, and CYFRA 21-1 in patients with lung cancer.","authors":"Aiwen Sun","doi":"10.1093/labmed/lmad020","DOIUrl":null,"url":null,"abstract":"Objective: The aim of the study was to assess the diagnostic value of tumor markers in discriminating between lung cancer and benign chest diseases (BCDs).Methods: There were 322 patients enrolled in this investigation including 180 cases of lung cancer and 142 cases of BCD. Serum neuron-specific enolase (NSE), cancer antigen 125, cancer antigen 19-9, squamous cell carcinoma-related antigen, and cytokeratin fragment 19 (CYFRA 21-1) were compared between different populations, cancer stages, and before and after treatment. Logistic regression and receiver operating characteristic curves were used to evaluate the diagnostic markers.Results: Both NSE and CYFRA 21-1 were significantly associated with lung cancer. The CYFRA 21-1 showed the best performance, as well as its combinations, for lung cancer diagnosis. It also showed significant change 6 months after radical surgery in lung cancer patients.Conclusion: The marker CYFRA 21-1 could be developed as an adjuvant marker for the early diagnosis of lung cancer and as a prognostic marker for lung cancer treatment.","PeriodicalId":17951,"journal":{"name":"Laboratory medicine","volume":" ","pages":"638-645"},"PeriodicalIF":0.0000,"publicationDate":"2023-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Laboratory medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/labmed/lmad020","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: The aim of the study was to assess the diagnostic value of tumor markers in discriminating between lung cancer and benign chest diseases (BCDs).

Methods: There were 322 patients enrolled in this investigation including 180 cases of lung cancer and 142 cases of BCD. Serum neuron-specific enolase (NSE), cancer antigen 125, cancer antigen 19-9, squamous cell carcinoma-related antigen, and cytokeratin fragment 19 (CYFRA 21-1) were compared between different populations, cancer stages, and before and after treatment. Logistic regression and receiver operating characteristic curves were used to evaluate the diagnostic markers.

Results: Both NSE and CYFRA 21-1 were significantly associated with lung cancer. The CYFRA 21-1 showed the best performance, as well as its combinations, for lung cancer diagnosis. It also showed significant change 6 months after radical surgery in lung cancer patients.

Conclusion: The marker CYFRA 21-1 could be developed as an adjuvant marker for the early diagnosis of lung cancer and as a prognostic marker for lung cancer treatment.

查看原文本刊更多论文

血清肿瘤标志物SCC、NSE、CA 125、CA 19-9和CYFRA 21-1在肺癌患者中的临床作用

目的：探讨肿瘤标志物在鉴别癌症与胸部良性疾病（BCDs）中的诊断价值。比较不同人群、癌症分期和治疗前后的血清神经元特异性烯醇化酶（NSE）、癌症抗原125、癌症抗原19-9、鳞状细胞癌相关抗原和细胞角蛋白片段19（CYFRA 21-1）。使用Logistic回归和受试者操作特征曲线来评估诊断标志物。结果：NSE和CYFRA 21-1均与癌症有显著相关性。CYFRA 21-1及其组合在肺癌癌症诊断中表现最佳。在癌症患者的根治性手术后6个月，它也显示出显著的变化。结论：CYFRA 21-1可作为癌症早期诊断的辅助标志物和癌症治疗的预后标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Laboratory medicine

自引率

0.00%

发文量